NTLA-2001 + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Trial Timeline
Dec 13, 2023 → Apr 1, 2028
NCT ID
NCT06128629About NTLA-2001 + Placebo
NTLA-2001 + Placebo is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy. The current trial status is active. This product is registered under clinical trial identifier NCT06128629. Target conditions include Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06128629 | Phase 3 | Active |
Competing Products
20 competing products in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |
| Coramitug | Novo Nordisk | Phase 1 | 32 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 22 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 22 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis | Pfizer | Approved | 84 |
| Tafamidis | Pfizer | Pre-clinical | 22 |